Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Ponatinib (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2018 Trial design presented at the Gastrointestinal Cancers Symposium.